|
|
|
European Pharmaceutical Contractor
|
|
In the early days, biomarkers were used primarily as physiological indicators for blood pressure or heart rate, as examples. A biomarker is an objective indication of a particular medical state observed from outside the patient, which can be measured accurately and reproducibly.
More recently, biomarkers, such as elevated prostate specific antigen, can be used as a molecular biomarker for prostate cancer or enzyme assays used as liver function tests. A biomarker is anything that can be used as an indicator of a disease state or some other physiological state of an organism.
According to Strimbu and Jorge, the use of biomarkers in basic and clinical research, as well as in clinical practice, has become so commonplace that their presence as primary endpoints in clinical trials is now accepted almost without question (1).
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Professor Christene Leiper attended Sydney University, RMIT Melbourne, and Bond University, Australia, and achieved a Professorship of Medicine and Life Sciences at Bond University in 2006. She also undertook research at Edinburgh University, Scotland, as part of her PhD. Christene has been a principal investigator for clinical trials, which enables her to operate across many disciplinary boundaries within clinical research in a coherent and productive manner. In 2007, she was appointed Director of Research at a Scottish CRO, which, in turn, led her to start her own CRO, Onorach, in 2009. |
|
|
|
|
|
 |
News and Press Releases |
 |
Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round
Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing
single cell analysis systems underpinned by its patented picodroplet
technology, announced today that it has closed an additional tranche of
investment of $2.9 million (£2.2 million), securing a total of $4.8
million (£3.7 million) in investment. The funding will be used as
working capital for the Company’s Cyto-Mine® Single Cell Analysis
System, expansion of the UK facility and enable the doubling of
personnel through the opening of a new US Sales Office and Demo Lab in
California.
More info >> |
|
 |
White Papers |
 |
|
Case Study: Getting the Client’s Trust - Oncology Program
Cmed Clinical Services
Five years ago, a biopharmaceutical company chose Cmed to conduct a
phase II oncology study. Cmed’s performance of the study and the good
relationship established with the Client led Cmed to be awarded a second
oncology trial which a couple of years ago was followed by a third,
fourth and fifth.
More info >> |
|
 |
Industry Events |
 |
CPhI Worldwide
5-7 November 2019, Frankfurt, Germany
Join the World's Largest Pharma Event As it Celebrates its 30th Anniversary!
Taking place from 5-7 November 2019 in Frankfurt, Germany, the event
will bring together more than 45,000 visiting pharma professionals from
around the globe and over 2,500 exhibiting pharma companies from every
stage of the pharmaceutical supply chain - from ingredients and
machinery to outsourcing services, packaging and more!
More info >> |
|
|
